Rockwell Medical, Inc.
RMTI Healthcare Drug Manufacturers Specialty & Generic
Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 32.0%, free cash flow fell 12.9% and total debt fell 1.73%, each against the same quarter a year earlier.
Follow RMTI
Rockwell Medical, Inc. (RMTI) P/E ratio
Rockwell Medical, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. | n/m |
| AYTU Aytu BioPharma, Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| TXMD TherapeuticsMD, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| UPC Universe Pharmaceuticals INC compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | 0.2× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)